Literature DB >> 6368290

Culture and phenotype of activated T-cells from patients with type I diabetes mellitus.

A R Hayward, M Herberger.   

Abstract

Blood T-cells from 28 patients with type I (insulin-dependent) diabetes (IDDM) of variable duration were examined for the Tac antigen by immunofluorescence, and for proliferation in the presence of interleukin 2 (IL 2). The mean percentage of Tac+ cells in patients whose IDDM was of less than 2-yr duration was 6.2% compared with 2% in patients whose IDDM was of 3 or more years' duration, or in healthy controls. The percentage of Tac+ cells in the patients' blood correlated positively with the amount of thymidine uptake in a 24-h culture of blood mononuclear cells and with the percentage of T-cell blasts generated in a 6-day culture. The patients' T-cell blasts stained with OKT 4 or OKT 8, suggesting that each of these subsets is present in the activated T-cell population in the patients' blood. The T-cell blasts did not show specificity for pork insulin in an antigen restimulation assay. There was no correlation between increased Tac+ cells and the presence or absence of islet cell antibodies. If T-cell activation in IDDM occurs as a result of recognition of islet cell antigens, our results suggest that both HLA-DR-restricted (OKT 4+) and A-, B-, and C-restricted (OKT 8+) T-cell subsets contribute.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6368290     DOI: 10.2337/diab.33.4.319

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  10 in total

1.  Immunoregulatory dysfunctions in type I diabetes: natural and antibody-dependent cellular cytotoxic activities.

Authors:  M P Nair; E W Lewis; S A Schwartz
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

2.  Defective autologous mixed leukocyte reaction in newly diagnosed type 1 diabetes mellitus.

Authors:  L Räsänen; H Hyöty; M Lehto; O P Kallioniemi; J Antonen; T Huupponen; J Karjalainen; P Leinikki
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

Review 3.  Multiple immunological abnormalities in patients with type 1 (insulin-dependent) diabetes mellitus.

Authors:  D W Drell; A L Notkins
Journal:  Diabetologia       Date:  1987-03       Impact factor: 10.122

4.  Persistent reduction of CD4/CD8 lymphocyte ratio and cell activation before the onset of type 1 (insulin-dependent) diabetes.

Authors:  L Al-Sakkaf; P Pozzilli; A C Tarn; G Schwarz; E A Gale; G F Bottazzo
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

Review 5.  The role of immunotherapy in type I diabetes mellitus.

Authors:  M E Geffner; B M Lippe
Journal:  West J Med       Date:  1987-03

6.  Study of T-cell activation in type I diabetic patients and pre-type I diabetic subjects by cytometric analysis: antigen expression defect in vitro.

Authors:  C Giordano; R De Maria; M Todaro; G Stassi; A Mattina; P Richiusa; G Galluzzo; F Pantó; A Galluzzo
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

7.  Insulin responses and lymphocyte subclasses in children with newly diagnosed insulin-dependent diabetes.

Authors:  T Scheinin; J Mäenpää; S Koskimies; B M Dean; G F Bottazzo; S Kontiainen
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

8.  Selective activation of T cells in newly diagnosed insulin-dependent diabetic patients: evidence for heterogeneity of T cell receptor usage.

Authors:  S Kontiainen; R Toomath; J Lowder; M Feldmann
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

9.  Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.

Authors:  A M Berghella; P Pellegrini; D Piancatelli; D Maccarone; T Del Beato; D Giubilei; A Pomidori; D Adorno; C U Casciani
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

10.  The majority of the activated T cells in the blood of insulin-dependent diabetes mellitus (IDDM) patients are CD4+.

Authors:  P De Berardinis; M Londei; M Kahan; F Balsano; S Kontiainen; E A Gale; G F Bottazzo; M Feldmann
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.